Skip to main content

Table 4 Risk factors analyzed by univariate and multivariate (Cox regression models) for disease-free survival (DFS) and overall survival (OS)

From: Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols

 

Univariate analysis

Multivariate analysis

 

DFS HR (95 % CI)

OS HR (95 % CI)

DFS HR (95 % CI)

OS HR (95 % CI)

Gender

Female

1

1

1

1

Male

0.59 (0.25–1.40)

0.57 (0.21–1.57)

0.41 (0.16–1.05)

0.41 (0.14–1.25)

Age, years

1.06 (1.01–1.12)

1.09 (1.02–1.16)

1.07 (1.01–1.12)

1.09 (1.02–1.16)

Budding

 No

1

1

1

1

 Yes

1.72 (0.67–4.44)

1.09 (0.31–3.85)

1.22 (0.35–4.16)

1.06 (0.23–4.87)

Fibrosis

 <50 %

1

1

1

1

 > = 50 %

1.98 (0.77–5.10)

1.23 (0.35–4.35)

1.21 (0.37–3.94)

1.01 (0.22–4.61)

Stage

 1

1

1

1

1

 2A

1.11 (0.42–2.93)

0.80 (0.26–2.46)

1.08 (0.35–3.30)

1.13 (0.31–4.13)

 2B

2.89 (0.58–14.35)

3.68 (0.71–19.00)

4.07 (0.63–26.08)

5.81 (0.77–43.92)

Lymph nodes retrieved

 > = 12

1

1

1

1

 <12

2.56 (1.09–6.25)

2.70 (1.03–7.69)

2.13 (0.76–5.88)

2.38 (0.71–8.33)

Vascular invasion

 No

1

1

1

1

 Yes

3.78 (1.12–12.91)

3.19 (0.72–14.15)

3.43 (0.87–13.58)

2.91 (0.59–14.31)

Lymphatic invasion

 No

1

1

1

1

 Yes

1.71 (0.63–4.67)

0.83 (0.19–3.69)

0.88 (0.26–2.94)

0.85 (0.09–2.89)

Site

 Right or trasversum

1

1

1

1

 Left or double

2.69 (1.04–6.93)

2.06 (0.70–6.04)

3.56 (1.24–10.21)

3.34 (0.98–11.84)

Chemotherapy

 No

1

1

1

1

 Yes

1.12 (0.38–3.34)

0.76 (0.17–3.37)

1.52 (0.39–5.97)

1.37 0.24–7.99)

  1. HR hazard ratio
  2. CI confidential interval